Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
13.62
-0.46 (-3.27%)
Mar 12, 2026, 10:23 AM EDT - Market open
Wave Life Sciences Employees
Wave Life Sciences had 317 employees as of December 31, 2025. The number of employees increased by 29 or 10.07% compared to the previous year.
Employees
317
Change (1Y)
29
Growth (1Y)
10.07%
Revenue / Employee
$134,785
Profits / Employee
-$644,726
Market Cap
2.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 317 | 29 | 10.07% | 317 | 0 |
| Dec 31, 2024 | 288 | 20 | 7.46% | 287 | 1 |
| Dec 31, 2023 | 268 | 16 | 6.35% | 266 | 2 |
| Dec 31, 2022 | 252 | 14 | 5.88% | 250 | 2 |
| Dec 31, 2021 | 238 | 18 | 8.18% | 235 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Apellis Pharmaceuticals | 739 |
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Vera Therapeutics | 224 |
| Immunome | 177 |
| Disc Medicine | 155 |
WVE News
- 5 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 7 days ago - Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - GlobeNewsWire
- 13 days ago - Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 21 days ago - Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 - GlobeNewsWire
- 5 weeks ago - Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
- 5 weeks ago - Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire